jueves, 3 de octubre de 2024

Effect of nirsevimab on hospitalisations for respiratory syncytial virus bronchiolitis in France, 2023–24: a modelling study

https://www.thelancet.com/journals/lanchi/article/PIIS2352-4642(24)00143-3/abstract?utm_campaign=update-lanchi&utm_medium=email&dgcid=hubspot_update_feature_updatealerts_lanchi&_hsenc=p2ANqtz-8EhYGhziESiOtZYwB4JZ2eIQhIhj6izBeRwXu2QBygWZLmDJH-j4kCM3X7-OOmNfgy-X2GWEZ-bbfsgS6whhMKNcraTg&_hsmi=327339247&utm_content=327302775&utm_source=hs_email

No hay comentarios:

Publicar un comentario